The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption

Pain Medicine

Volumn 10, Issue 5, 2009, Pages 799-805

  Candiotti, Keith A ^a   Yang, Zongqi ^a   Rodriguez, Yiliam ^a   Crescimone, Andres ^a   Sanchez, Greys C ^a   Takacs, Peter ^a   Medina, Carlos ^a   Zhang, Yanping ^a   Liu, Huanliang ^a   Gitlin, Melvin C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2D6; Genetic polymorphisms; Morphine consumption; Postoperative pain; Ultra rapid CYP2D6 metabolizers

Indexed keywords

CYTOCHROME P450 2D6; FENTANYL; MORPHINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; DRUG UPTAKE; DRUG USE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SURGICAL PATIENT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANALGESICS, OPIOID; ANESTHESIA; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; KINETICS; MALE; MIDDLE AGED; MORPHINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAIN, POSTOPERATIVE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 68349144595     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00641.x     Document Type: Article

References (19)

1. Fishbain DA, Fishbain D, Lewis J, et al. Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time? A structured review. Pain Med 2004;5:81-93.
2. Desmeules JA, Piguet V, Ehret GB, Dayer P. Pharmacogenetics, pharmacokinetics, and analgesia. In: Mogil JS, ed. The Genetics of Pain, Progress in Pain Research and Management. Seattle, WA: IASP Press; 2004: 211-37.
3. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 1997;14:157-67.
4. Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology 2003;98:1415-21.
5. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81:429-44.
6. Glattard E, Muller A, Aunis D, Metz-Boutigue MH, Stefano GB, Goumon Y. Rethinking the opiate system? Morphine and morphine-6-glucuronide as new endocrine and neuroendocrine mediators. Med Sci Monit 2006;12:SR25-7.
7. Guarna M, Bianchi E, Bartolini A, et al. Endogenous morphine modulates acute thermonociception in mice. J Neurochem 2002;80:271-7.
8. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998;249:838-43.
9. Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: Actions and mechanisms. Med Res Rev 2005;25:521-44.
10. Cadet P, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu 3, a novel alternatively spliced variant of the human mu opiate receptor gene. J Immunol 2003;170:5118-23.
11. Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. J Immunol 2005;175:7357-62.
12. Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: Clinical implications. Cancer J 2002;8:405-14.
13. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-9.
14. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005;102:543-9.
15. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-65.
16. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990;48:686-93.
17. Funae Y, Kishimoto W, Cho T, Niwa T, Hiroi T. CYP2D in the brain. Drug Metab Pharmacokinet 2003;18:337-49.
18. Zhu W, Mantione KJ, Shen L. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: Cyp2d6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Med Sci Monit 2005;11:BR397-404.
19. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993;53:335-9.